Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis

Cardiovascular Drugs and Therapy

Volumn 27, Issue 6, 2013, Pages 521-530

  Jia, Li Xin ^a   Qi, Guan Ming ^a   Liu, Ou ^a   Li, Tao Tao ^a   Yang, Min ^a   Cui, Wei ^a   Zhang, Wen Mei ^a   Qi, Yong Fen ^a   Du, Jie ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cardiac fibrosis; Clopidogrel; Hypertension; Inflammation; Platelet activation

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; CD45 ANTIGEN; CLOPIDOGREL; FIBRINOGEN RECEPTOR; INTERLEUKIN 1BETA; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDITIS; CONTROLLED STUDY; HEART MUSCLE FIBROSIS; HEMOSTASIS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; MACROPHAGE; MALE; MOUSE; MYOFIBROBLAST; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; THROMBOCYTE ACTIVATION;

ANGIOTENSIN II; ANIMALS; FIBROSIS; HYPERTENSION; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED C57BL; MYOCARDITIS; MYOCARDIUM; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84892366182     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-013-6471-z     Document Type: Article

References (49)

1. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83(6):1849-65.
2. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension.Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res. 1991;69(1):107-15.
3. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63(3):423-32.
4. Huang XR, Chung AC, Yang F, YueW, Deng C, Lau CP, et al. Smad3 mediates cardiac inflammation and fibrosis in angiotensin II-induced hypertensive cardiac remodeling. Hypertension. 2010;55(5):1165-71.
5. McCalmon SA, Desjardins DM, Ahmad S, Davidoff KS, Snyder CM, Sato K, et al. Modulation of angiotensin II-mediated cardiac remodeling by the MEF2A target gene Xirp2. Circ Res. 2010;106(5):952-60.
6. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 2007;117(3):524-9.
7. Klanke B, Cordasic N, Hartner A, Schmieder RE, Veelken R, Hilgers KF. Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension. Nephrol Dial Transplant. 2008;23(11):3456-63.
8. Qi G, Jia L, Li Y, Bian Y, Cheng J, Li H, et al. Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent. Cardiovasc Toxicol. 2011;11(2):157-67.
9. Massberg S, Gruner S, Konrad I, Garcia Arguinzonis MI, Eigenthaler M, Hemler K, et al. Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice. Blood. 2004;103(1):136-42.
10. Massberg S, Enders G, Matos FC, Tomic LI, Leiderer R, Eisenmenger S, et al. Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood. 1999;94(11):3829-38.
11. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115(12):3378-84.
12. Semple JW, Italiano Jr JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11(4):264-74.
13. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res. 2007;100(1):27-40.
14. Danese S, de la Motte C, Reyes BM, Sans M, Levine AD, Fiocchi C. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol. 2004;172(4):2011-5.
15. Savi P, Zachayus JL, Delesque-Touchard N, Labouret C, Herve C, Uzabiaga MF, et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A. 2006;103(29):11069-74.
16. Evangelista V, Manarini S, Dell'Elba G, Martelli N, Napoleone E, Di Santo A, et al. Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thromb Haemost. 2005;94(3):568-77.
17. Hashimoto M, Sugidachi A, Isobe T, Niitsu Y, Ogawa T, Jakubowski JA, et al. The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: evidence for specific inhibition of P2Y12 receptors by prasugrel. Biochem Pharmacol. 2007;74(7):1003-9.
18. Yang M, Zheng J, Miao Y, Wang Y, Cui W, Guo J, et al. Serumglucocorticoid regulated kinase 1 regulates alternatively activated macrophage polarization contributing to angiotensin II-induced inflammation and cardiac fibrosis. Arterioscler Thromb Vasc Biol. 2012;32(7):1675-86.
19. Wang J, Xu N, Feng X, Hou N, Zhang J, Cheng X, et al. Targeted disruption of Smad4 in cardiomyocytes results in cardiac hypertrophy and heart failure. Circ Res. 2005;97(8):821-8.
20. Gresele P, Momi S, Berrettini M, Nenci GG, Schwarz HP, Semeraro N, et al. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. J Clin Invest. 1998;101(3):667-76.
21. Pan L, Li Y, Jia L, Qin Y, Qi G, Cheng J, et al. Cathepsin S deficiency results in abnormal accumulation of autophagosomes in macrophages and enhances Ang II-induced cardiac inflammation. PLoS One. 2012;7(4):e35315.
22. Ma F, Li Y, Jia L, Han Y, Cheng J, Li H, et al. Macrophagestimulated cardiac fibroblast production of IL-6 is essential for TGF beta/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One. 2012;7(5):e35144.
23. Han YL, Li YL, Jia LX, Cheng JZ, Qi YF, Zhang HJ, et al. Reciprocal interaction between macrophages and T cells stimulates IFN-gamma and MCP-1 production in Ang II-induced cardiac inflammation and fibrosis. PLoS One. 2012;7(5):e35506.
24. Li Y, Zhang C,Wu Y, Han Y, Cui W, Jia L, et al. Interleukin-12p35 deletion promotes CD4 T-cell-dependent macrophage differentiation and enhances angiotensin II-Induced cardiac fibrosis. Arterioscler Thromb Vasc Biol. 2012;32(7):1662-74.
25. Wysocki J, Ye M, Rodriguez E, Gonzalez-Pacheco FR, Barrios C, Evora K, et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension. 2010;55(1):90-8.
26. Cavalli A, Lattion AL, Hummler E, Nenniger M, Pedrazzini T, Aubert JF, et al. Decreased blood pressure response in mice deficient of the alpha1b-adrenergic receptor. Proc Natl Acad Sci U S A. 1997;94(21):11589-94.
27. Akan M, Cakir B, Misirlioglu A, Yildirim S, Taylan G, Akoz T. Effects of clopidogrel and high dose aspirin on survival of skin flaps in rats. Scand J Plast Reconstr Surg Hand Surg. 2005;39(1):7-10.
28. Jia L, Li Y, Xiao C, Du J. Angiotensin II induces inflammation leading to cardiac remodeling. Front Biosci. 2012;17:221-31.
29. Honsho S, Nishikawa S, Amano K, Zen K, Adachi Y, Kishita E, et al. Pressure-mediated hypertrophy and mechanical stretch induces IL-1 release and subsequent IGF-1 generation to maintain compensative hypertrophy by affecting Akt and JNK pathways. Circ Res. 2009;105(11):1149-58.
30. Bujak M, Dobaczewski M, Chatila K, Mendoza LH, Li N, Reddy A, et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol. 2008;173(1):57-67.
31. Utsugisawa K, Kizawa H, Nagane Y, Kondoh R, Iwa Y, Akutsu H, et al. Biphasic effects of angiotensin II and receptor antagonism on aggregability and protein kinase C phosphorylation in human platelets. Thromb Haemost. 2005;94(5):1012-8.
32. Boilard E, Blanco P, Nigrovic PA. Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol. 2012;8(9):534-42.
33. Ferroni P, Guagnano MT, Falco A, Paoletti V, Manigrasso MR, Michetti N, et al. Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria. Clin Sci (Lond). 2008;114(6):449-55.
34. Davi G, Gresele P, Violi F, Basili S, Catalano M, Giammarresi C, et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation. 1997;96(1):69-75.
35. Spencer CG, Gurney D, Blann AD, Beevers DG, Lip GY. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension. 2002;40(1):61-6.
36. Nadar SK, Blann AD, Kamath S, Beevers DG, Lip GY. Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol. 2004;44(2):415-22.
37. Larsson PT, Schwieler JH, Wallen NH. Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagul Fibrinolysis. 2000;11(1):61-9.
38. Kalinowski L,Matys T, Chabielska E, BuczkoW, Malinski T. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension. 2002;40(4):521-7.
39. Totani L, EvangelistaV. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler ThrombVasc Biol. 2010;30(12):2357-61.
40. Liu Y, Gao XM, Fang L, Jennings NL, Su Y, Xu Q, et al. Novel role of platelets in mediating inflammatory responses and ventricular rupture or remodeling following myocardial infarction. Arterioscler Thromb Vasc Biol. 2011;31(4):834-41.
41. Hara T, Shimizu K, Ogawa F, Yanaba K, Iwata Y, Muroi E, et al. Platelets control leukocyte recruitment in a murine model of cutaneous arthus reaction. Am J Pathol. 2010;176(1):259-69.
42. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003;9(1):61-7.
43. Pitchford SC, Momi S, Giannini S, Casali L, Spina D, Page CP, et al. Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. Blood. 2005;105(5):2074-81.
44. Wang Y, Sakuma M, Chen Z, Ustinov V, Shi C, Croce K, et al. Leukocyte engagement of platelet glycoprotein Ibalpha via the integrin Mac-1 is critical for the biological response to vascular injury. Circulation. 2005;112(19):2993-3000.
45. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost. 2001;86(3):746-56.
46. Romo GM, Dong JF, Schade AJ, Gardiner EE, Kansas GS, Li CQ, et al. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med. 1999;190(6):803-14.
47. Wick G, Backovic A, Rabensteiner E, Plank N, Schwentner C, Sgonc R. The immunology of fibrosis: innate and adaptive responses. Trends Immunol. 2010;31(3):110-9.
48. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199-210.
49. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem. 1983;258(11):7155-60. China